Clinical trial NCT01524874: Comparative Effectiveness of Vitamin D and Repletion Strategies
Official title: A Comparative Effectiveness Trial of High-quality Vitamin D3 Nutritional Supplements to Replete Serum Vitamin D
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypovitaminosis D
Insulin Resistance
Diabetes
Keywords: vitamin d
cholecalciferol
nutritional supplements
hypovitaminosis d
klotho
toll like receptor 4
Lead sponsor: Bastyr University
Sponsor class: OTHER
Collaborators: name: Diabetes Action Research and Education Foundation
First posted: 2012-02-02
Enrollment: 66
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The importance of vitamin D (VitD) in the prevention and treatment of human health conditions has gained increased attention in recent years. As a result, medical providers of all categories are screening clinical VitD status frequently, yet become challenged with how to best advise patients regarding repletion of VitD status, i.e. which form of VitD replacement is most effective. It has been recognized that to achieve significant effects - serum concentrations \>30ng/ml (75 nmol/ml) - it is necessary, as well as safe, to recommend substantially higher doses than were previously thought sufficient. These higher doses can be easily achieved orally. This clinical trial aims to compare absorption of three available forms of this fat-soluble vitamin, due to the potential differences in absorption of different preparations. High-quality powdered, chewable and lipid-emulsified VitD are readily available as supplements, yet these have not been systematically compared. This three-arm, randomized clinical trial will compare the difference in serum 25-hydroxycholecalciferol (25-OH)D concentration between the three arms at baseline and after random administration of one of the three VitD preparations for 12-weeks at a dosage of 10,000 IU VitD per day. The investigators hypothesize that the three forms of vitD will result in an equivalent increase in serum 25OHD.

Detailed description: VitD has numerous hormonal effects, including regulation of Ca2+ and Mg2+, as well as effects on numerous genes, including insulin and androgens. Mounting literature demonstrates associations between VitD insufficiency and cancer, diabetes and heart disease. VitD insufficiency, defined by concentration of serum 25-hydroxycholecalciferol (25-OHD) \<33ng/ml (82.5 nmol/ml), is common at all latitudes; the prevalence is estimated at \~35% in "healthy" populations. VitD testing and replacement is gaining popularity in clinical practice. It is not known whether there is a difference in the effect of equivalent doses of emulsified vs. non-emulsified cholecalciferol (VitD3) supplementation, reflected by quantitative changes in serum 25-OHD. However, clinical observations revealed that in an average of 4.4 months, subjects taking 4000 iu daily of the emulsified form of cholecalciferol improved their 25-OHD levels by 6.76 ng/mL more than those taking 5,000 iu daily of the non-emulsified form. The safety of taking 10,000 IU/day has been confirmed. Taking this dose for 12 weeks should cause a robust increase in serum 25-OHD. This study will provide preliminary data comparing three high quality VitD3 supplements, one a powdered capsule, one a chewable tablet, and the other a lipid-emulsified liquid. Future studies will compare the "better" supplement to conventional VitD replacement using VitD2.

Eligibility criteria: Inclusion Criteria:

* Provision of informed consent
* Between18-65 years of age; there is an age-related decline in the absorption, transport or liver hydroxylation of orally-consumed VitD (Harris, 1999) therefore adults older than 65 will be excluded. This population is also at greater risk of being on medications with potential medication interactions, e.g. anticoagulants.
* Willingness to perform baseline screening tests: serum 25-OHD, CBC, Comprehensive metabolic chemistry panel (electrolytes, hepatic and renal function tests, lipids, HgA1C, insulin and glucose)
* Screening serum 25-OHD \<33ng/ml (82.5 nmol/ml). If \>=33ng/ml (82.5 nmol/ml), subjects will participate in the research study as baseline controls for the nested studies of Klotho and TLR-4.
* Ability to read and speak English
* Willingness to be randomized to one of three active treatments for 3 months

Exclusion Criteria:

* Subjects who have a serum baseline 25-OHD \>=33ng/ml (82.5 nmol/ml) will be excluded once the VitD sufficient baseline control recruitment goal is met
* Subjects who have historical or current use of extra-dietary VitD, other than what is in a multivitamin, for the previous 3 months.
* LFTs: AST\>60 U/L; ALT\>65 U/L; Alkaline phosphatase \>120 U/L. Total bilirubin\>1.5 mg/dL
* Serum creatinine\>1.4 mg/dL; BUN \>25 mg/dL5. Subjects who are pregnant, or could become pregnant, unless they are using regular birth control (OCPs, condoms, IUD).
* Subjects who have established osteoporosis.
* Subjects who have history or symptoms of a parathyroid disorder.
* Subjects who have difficulty swallowing pills.
* Subjects who are unwilling to use sunscreen.
* Subjects who have had a past adverse reaction to sunscreen.
* Subjects who are taking medications over the previous 3 months that interfere with the metabolism of VitD (anti-convulsants, anti-coagulants, oral corticosteroids, or barbiturates).
* Subjects with any psychological conditions or substance abuse that may make the subject non- adherent, such as history of bipolar disorder, mania, untreated anxiety or other mood disorder, as determined by the site PI.
* Other severe illness or mental incapacity that, in the opinion of the site PI, would render the potential subject incapable of participating in the study.
* Allergy to sesame oil base
* Heart arrhythmia

Primary outcomes:
measure: Change in mean serum 25-hydroxycholecalciferol concentration
timeFrame: Baseline and 12 weeks
Secondary outcomes:
measure: Proportion of participants reaching 25-hydroxycholecalciferol concentration >=33ng/ml (82.5 nmol/ml) between groups
timeFrame: 12 weeks
measure: Change in mean Klotho protein concentration
timeFrame: Baseline and 12 weeks
measure: Change in Toll-like receptor concentration in monocytes
timeFrame: Baseline and 12 weeks
measure: Change in mean cardiometabolic risk factors
timeFrame: Baseline- 12 weeks
Other outcomes:
Locations:
city: Kailua Kona
country: United States
facility: Lokahi Health Center
state: Hawaii
city: Kenmore
country: United States
facility: Bastyr University
state: Washington
Study officials:
affiliation: Bastyr University
name: Ryan Bradley, ND, MPH
role: PRINCIPAL_INVESTIGATOR
References: